Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

BACKGROUND: Capecitabine and irinotecan combination therapy (XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer (mCRC). Recently, in the Association of Medical Oncology of the German Cancer Society (AIO) 0604 trial, tri-weekly XELIRI plus bevacizumab, with reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotaka, Masahito, Xu, Ruihua, Muro, Kei, Park, Young Suk, Morita, Satoshi, Iwasa, Satoru, Uetake, Hiroyuki, Nishina, Tomohiro, Nozawa, Hiroaki, Matsumoto, Hiroshi, Yamazaki, Kentaro, Han, Sae-Won, Wang, Wei, Ahn, Joong Bae, Deng, Yanhong, Cho, Sang-Hee, Ba, Yi, Lee, Keun-Wook, Zhang, Tao, Satoh, Taroh, Buyse, Marc E., Ryoo, Baek-Yeol, Shen, Lin, Sakamoto, Junichi, Kim, Tae Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178089/
https://www.ncbi.nlm.nih.gov/pubmed/28007025
http://dx.doi.org/10.1186/s40880-016-0166-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178089/
https://www.ncbi.nlm.nih.gov/pubmed/28007025
http://dx.doi.org/10.1186/s40880-016-0166-3

Ejemplares similares